Nadia Bodkin, Pharm.D., M.S.
Nadia is a seasoned rare disease patient advocate, born with three main rare conditions herself. Immediately after graduation, Nadia went straight into advocacy through EDSers United, a foundation she founded as a student. Nadia has held leadership positions at several rare disease advocacy focused organizations assisting in everything between nonprofit management to event planning. She is currently the Chief Executive Officer for Blaze Therapeutics and is one of the founding members of New Love Ventures. Nadia also founded and currently facilitates the coordination of the Rare Advocacy Movement's activities along with her fellow RAM colleagues.
 
As a result of being born with rare genetic conditions herself, Nadia put her medical education and research background to use and was able to effectively expand her life expectancy, while co-founding several rare disease and humanity-focused philanthropic initiatives. Nadia functions on the premise of making the most of the time that one has on Earth; and she is doing just that by dedicating her efforts towards improving the lives of those affected by rare conditions, U.S. Veterans, and other like-minded individuals through novel patient advocacy initiatives and innovative multi-stakeholder collaborations.
Follow Nadia on social media @NadiaBodkin
Featured Article: Rare Leader by Global Genes
  • LinkedIn - White Circle

The Rare Advocacy Movement (RAM) is a rare disease focused community advocacy initiative focused on addressing the issues that affect the real world people of the rare disease community.  RAM serves as a community-based professional network and Center of Insight (COI) for rare disease focused stakeholders seeking authentic connections and unadulterated community insights. The RAM membership is comprised of a network of patient advocacy community expert professionals that have vowed to abide by the established Code of Conduct for Membership. As a result, every current RAM member has made a public vow to always act in the best interest of the rare disease community.